COMPASS Pathways plc (CMPS) stock forecast & analysis
8.41
NasdaqGS · USDDelayed by 15 minutes
Down: -3.16, -27.3%
8.80Up: +0.39, +4.6%
1 analysis
Latest analysis: · verdict locked
- Open
- 11.71
- Previous close
- 11.57
- Day range
- 7.54 – 11.76
- 52-week range
- 4.88 – 15.87
- Volume (shares)
- 16.79M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 138.48M
- P/E ratio
- Not available
- Dividend yield
- 0.00%
- Beta
- 2.41
- Market cap
- 1.16B
Market Scanner’s AI analysis of COMPASS Pathways plc (CMPS), updated November 2026: CMPS experienced a significant volume-driven price breakdown on competitive fears, breaking below key moving averages.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of COMPASS Pathways plc (CMPS) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
CMPS experienced a significant volume-driven price breakdown on competitive fears, breaking below key moving averages.
Recent analyses covered a substantial price decline for CMPS, marked by a significant increase in trading volume and a breakdown below its 50-day and 200-day moving averages. The company is pre-revenue and clinical-stage, with its next earnings report due imminently. The sell-off was attributed to unconfirmed fears of competitive pressure in psychedelic therapies.
CMPS news & sentiment
Market sentiment turned negative on news of competitive threats in psychedelic therapies, contributing to a significant price breakdown. Social media commentary was largely promotional, lacking specific market-moving data.
CMPS technical picture
CMPS experienced a significant price breakdown on heavy volume, falling below its 50-day and 200-day moving averages. Price action was 34.3% below the 50-day SMA and 19.2% below the 200-day SMA, with the 50-day SMA declining while the 200-day SMA was slowly rising.
Fundamentals
The company is pre-revenue and clinical-stage, with no revenue reported and significant operating losses. Cash flow data confirms its early-stage status, and valuation metrics are not applicable in the absence of revenue.
Factors discussed — risks
- Price broke below 50-day and 200-day SMAs
- Significant price decline on high volume
- Pre-revenue and clinical-stage company
- Fears of competitive FDA race in psychedelic therapies
- Price action
- Technical levels
- Competitive landscape
- Clinical-stage development
Summary updated .
CMPS technical indicators
Common technical indicators for CMPS, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 12.81 | Price below |
| 10-day exponential moving average | 11.12 | Price below |
| Relative strength index (14-day) | 28.09 | Oversold |
| MACD line (12/26/9) | -0.5226 | Below its signal line |
| Bollinger bands (20-day, 2σ) | 9.83 – 12.97 | Price below the lower band |
Analyses
Recent CMPS.US analyses are locked — sign in to read them or generate a fresh one.
Locked
Unlock in the library — 1 newer report
Sign in to unlock the 2026-11-02 CMPS.US analysis
Get the verdict — free
Frequently asked questions
- What are the risks for COMPASS Pathways plc?
- Risks discussed included the company's pre-revenue status, a significant price decline on high trading volume, and fears surrounding competitive pressures in the psychedelic therapy market.
- Is COMPASS Pathways plc bullish or bearish?
- Recent AI analyses of COMPASS Pathways plc examined factors on both sides. Discussed upside: The analyses discussed potential upside drivers related to the company's progress in clinical-stage development within the psychedelic therapy sector. Discussed risks: Risks discussed included the company's pre-revenue status, a significant price decline on high trading volume, and fears surrounding competitive pressures in the psychedelic therapy market. These are descriptive observations, not a recommendation.
- What is the latest sentiment on COMPASS Pathways plc?
- Market sentiment turned negative on news of competitive threats in psychedelic therapies, contributing to a significant price breakdown. Social media commentary was largely promotional, lacking specific market-moving data.
- How does Market Scanner analyse COMPASS Pathways plc?
- Every analysis of COMPASS Pathways plc runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
What are the risks for COMPASS Pathways plc?
Risks discussed included the company's pre-revenue status, a significant price decline on high trading volume, and fears surrounding competitive pressures in the psychedelic therapy market.
Is COMPASS Pathways plc bullish or bearish?
Recent AI analyses of COMPASS Pathways plc examined factors on both sides. Discussed upside: The analyses discussed potential upside drivers related to the company's progress in clinical-stage development within the psychedelic therapy sector. Discussed risks: Risks discussed included the company's pre-revenue status, a significant price decline on high trading volume, and fears surrounding competitive pressures in the psychedelic therapy market. These are descriptive observations, not a recommendation.
What is the latest sentiment on COMPASS Pathways plc?
Market sentiment turned negative on news of competitive threats in psychedelic therapies, contributing to a significant price breakdown. Social media commentary was largely promotional, lacking specific market-moving data.
How does Market Scanner analyse COMPASS Pathways plc?
Every analysis of COMPASS Pathways plc runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.
Read the methodology- Bundles used
- claude-medium-v2
Run a fresh CMPS.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.